Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.

MLA

Morio, Kei, et al. “Effects of ITPA Polymorphism on Decrease of Hemoglobin during Simeprevir, Peg-Interferon, and Ribavirin Combination Treatment for Chronic Hepatitis C.” Hepatology Research, vol. 46, no. 12, Nov. 2016, pp. 1256–63. EBSCOhost, https://doi.org/10.1111/hepr.12681.

APA

Morio, K., Imamura, M., Kawakami, Y., Morio, R., Hatooka, M., Kan, H., Fujino, H., Fukuhara, T., Kobayashi, T., Masaki, K., Ono, A., Nakahara, T., Urabe, A., Yokoyama, S., Nagaoki, Y., Kawaoka, T., Hiraga, N., Tsuge, M., Hiramatsu, A., & Hayes, C. N. (2016). Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. Hepatology Research, 46(12), 1256–1263. https://doi.org/10.1111/hepr.12681

Chicago

Morio, Kei, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Masahiro Hatooka, Hiromi Kan, Hatsue Fujino, et al. 2016. “Effects of ITPA Polymorphism on Decrease of Hemoglobin during Simeprevir, Peg-Interferon, and Ribavirin Combination Treatment for Chronic Hepatitis C.” Hepatology Research 46 (12): 1256–63. doi:10.1111/hepr.12681.